Hauck & Aufhaeuser set a €135.00 ($156.98) price target on Sartorius (FRA:SRT3) in a research report sent to investors on Friday, Borsen Zeitung reports. The firm currently has a sell rating on the stock.
SRT3 has been the subject of several other research reports. HSBC set a €150.00 ($174.42) price objective on Sartorius and gave the company a neutral rating in a report on Friday, July 12th. Kepler Capital Markets set a €128.00 ($148.84) price objective on Sartorius and gave the company a sell rating in a report on Tuesday, June 11th. UBS Group set a €184.00 ($213.95) price objective on Sartorius and gave the company a neutral rating in a report on Friday, July 19th. Berenberg Bank set a €145.00 ($168.60) price objective on Sartorius and gave the company a sell rating in a report on Thursday, July 25th. Finally, Warburg Research set a €184.00 ($213.95) price objective on Sartorius and gave the company a neutral rating in a report on Tuesday, July 23rd. Five analysts have rated the stock with a sell rating and four have given a hold rating to the company. The stock presently has a consensus rating of Sell and an average target price of €146.50 ($170.35).
Sartorius stock opened at €174.40 ($202.79) on Friday. The business has a fifty day moving average of €181.04 and a two-hundred day moving average of €164.93. Sartorius has a twelve month low of €71.00 ($82.56) and a twelve month high of €124.70 ($145.00).
Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors.
Featured Article: How does a security become overbought?
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.